Published in Ther Clin Risk Manag on March 20, 2014
Systematic analysis of the association between gut flora and obesity through high-throughput sequencing and bioinformatics approaches. Biomed Res Int (2014) 0.86
Manipulating the circadian and sleep cycles to protect against metabolic disease. Front Endocrinol (Lausanne) (2015) 0.82
Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: a pilot study. Front Physiol (2015) 0.81
Prediabetes, elevated iron and all-cause mortality: a cohort study. BMJ Open (2014) 0.79
Amplitude of sensory nerve action potential in early stage diabetic peripheral neuropathy: an analysis of 500 cases. Neural Regen Res (2014) 0.79
Vitamin D status and its association with insulin resistance among type 2 diabetics: A case -control study in Ghana. PLoS One (2017) 0.79
Carnitine Palmitoyltransferase 1b Deficient Mice Develop Severe Insulin Resistance After Prolonged High Fat Diet Feeding. J Diabetes Metab (2014) 0.78
Stinging Nettle (Urtica dioica L.) Attenuates FFA Induced Ceramide Accumulation in 3T3-L1 Adipocytes in an Adiponectin Dependent Manner. PLoS One (2016) 0.75
Ethical issues relating to renal transplantation from prediabetic living donor. BMC Med Ethics (2014) 0.75
An extract of Urtica dioica L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A). Sci Rep (2016) 0.75
Evaluation of US Veterans Nutrition Education for Diabetes Prevention. J Nutr Educ Behav (2016) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Prevalence of diabetes among men and women in China. N Engl J Med (2010) 19.98
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
Economic costs of diabetes in the U.S. in 2012. Diabetes Care (2013) 11.74
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet (2006) 11.64
Using community-based participatory research to address health disparities. Health Promot Pract (2006) 11.61
Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA (2009) 11.52
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet (2008) 9.03
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia (2006) 8.18
The thrifty phenotype hypothesis. Br Med Bull (2001) 7.98
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 7.24
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med (2010) 6.63
Prediabetes: a high-risk state for diabetes development. Lancet (2012) 6.42
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med (2012) 6.19
Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med (2001) 6.15
Community-based participatory research: assessing the evidence. Evid Rep Technol Assess (Summ) (2004) 6.13
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 6.05
Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med (2008) 5.40
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med (2005) 5.27
Community-based research partnerships: challenges and opportunities. J Urban Health (2005) 5.25
Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab (2008) 4.86
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care (2006) 4.72
Can communities and academia work together on public health research? Evaluation results from a community-based participatory research partnership in Detroit. J Urban Health (2001) 4.56
Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med (2007) 4.54
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53
Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet (2012) 4.33
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet (2002) 4.29
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Physical inactivity: the biggest public health problem of the 21st century. Br J Sports Med (2009) 4.23
Building and maintaining trust in a community-based participatory research partnership. Am J Public Health (2008) 3.85
Sustaining interventions in community systems: on the relationship between researchers and communities. Health Psychol (1995) 3.42
Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry (2009) 3.33
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
Improving collaboration between researchers and communities. Public Health Rep (2000) 3.13
Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol (2010) 3.12
Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol (2012) 3.09
Broadening participation in community problem solving: a multidisciplinary model to support collaborative practice and research. J Urban Health (2003) 2.94
Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes (2005) 2.82
Community science: bridging the gap between science and practice with community-centered models. Am J Community Psychol (2003) 2.74
Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia (2004) 2.72
Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health (2007) 2.53
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes (2009) 2.51
Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care (2010) 2.50
Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care (1995) 2.44
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes (2006) 2.40
Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol (2012) 2.39
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract (2005) 2.38
Community-based participatory research: opportunities, challenges, and the need for a common language. J Gen Intern Med (2003) 2.37
Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care (2007) 2.30
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care (2007) 2.20
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care (2007) 2.11
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med (2008) 2.10
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) (2011) 2.08
A planning framework for community empowerment goals within health promotion. Health Policy Plan (2000) 2.00
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99
A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab (2011) 1.98
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr (2011) 1.94
Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis (2004) 1.94
Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes (2001) 1.84
The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med (2008) 1.83
Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care (2010) 1.82
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study--secondary analysis of the randomized trial. PLoS One (2009) 1.68
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) (2012) 1.66
Circadian disruption leads to insulin resistance and obesity. Curr Biol (2013) 1.66
The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis (2011) 1.63
Type 2 diabetes prevention in the real world: three-year results of the GOAL lifestyle implementation trial. Diabetes Care (2009) 1.62
Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes Care (2009) 1.61
"You've gotta know the community": minority women make recommendations about community-focused health research. Women Health (2008) 1.60
Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract (2007) 1.59
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A (1999) 1.58
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia (2004) 1.57
Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr Mol Med (2008) 1.57
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care (2007) 1.53
Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab (2011) 1.53
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care (2010) 1.50
The European perspective of type 2 diabetes prevention: diabetes in Europe--prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes (2008) 1.49
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes (2007) 1.47
Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol Metab (2009) 1.46
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med (2007) 1.43
Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease. Eur J Cardiovasc Prev Rehabil (2008) 1.39
Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 1.38